Bipolar disorder (BPD) and schizophrenia (SZ) are severe psychiatric illnesses with a
combined prevalence of 4%. A disturbance of energy metabolism is frequently observed in …

Identifying biomarkers that can be used as diagnostics or predictors of treatment response
(theranostics) in people with schizophrenia (Sz) will be an important step towards being able …

Schizophrenia is a heterogeneous psychiatric disorder with a broad spectrum of clinical and
biological manifestations. Due to the lack of objective tests, the accurate diagnosis and …

Abstract In 2015,~ 800,000 people died by suicide worldwide. For every death by suicide
there are as many as 25 suicide attempts, which can result in serious injury even when not …

Despite recent advances in understanding the pathophysiology of schizophrenia and the
mechanisms of antipsychotic drug action, the development of biomarkers for diagnosis and …

Though the pathophysiology of schizophrenia remains poorly understood, altered brain
energy metabolism is increasingly implicated. Here, we conduct meta-analyses of the …

Background: Although primarily a neurodegenerative process, there is increasing
awareness of peripheral disease mechanisms in Parkinson's disease. To investigate …

Synaptic neurotransmission relies on maintenance of the synapse and meeting the energy
demands of neurons. Defects in excitatory and inhibitory synapses have been implicated in …

On observing schizophrenia from a clinical point of view up to its molecular basis, one may
conclude that this is likely to be one of the most complex human disorders to be …

Schizophrenia is a psychiatric illness that affects approximately 30 million people worldwide.
Converging lines of evidence suggest that mitochondrial function may be compromised in …